The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial treatment

Not Open Access | Nanotized curcumin-benzothiophene conjugate: A potential combination for treatment of cerebral malaria

October 13, 2020 - 12:50 -- NOT Open Access
Author(s): 
Ghosh A, Banerjee T
Reference: 
IUBMB Life. 2020 Oct 9.

The declining effectiveness of the available antimalarial drugs due to drug resistance requires a continued effort to develop new therapeutic approaches. In this context, combination therapies hold a great promise for developing effective first-line antimalarial treatments for reducing malaria mortality. The present study explores the antimalarial efficacy of nanotized formulation of curcumin in combination with benzothiophene compound 6 (3-bromo-N-(4-fluorobenzyl)-benzo[b]thiophene-2-carboxamide) with a view to achieve better efficacy at a very low dose in comparison to that accomplished with monotherapy alone.

Not Open Access | Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients

October 1, 2020 - 15:46 -- NOT Open Access
Author(s): 
Almeida AC, Elias ABR, Marques MP, de Melo GC, da Costa AG, Figueiredo EFG, Brasil LW, Rodrigues-Soares F, Monteiro WM, de Lacerda MVG, Lanchote VL, Suarez-Kurtz G
Reference: 
Br J Clin Pharmacol. 2020 Sep 30

To investigate the impact of Plasmodium vivax malaria and chloroquine‐primaquine chemotherapy on CYP2D6 and CYP2C19 activity in patients from the Brazilian Amazon.

NOT Open Access | Treating Severe Malaria

October 1, 2020 - 15:44 -- NOT Open Access
Author(s): 
Berman JD
Reference: 
Clin Infect Dis. 2020 Sep 30:ciaa887

In “Concomitant bacteremia in adults with severe falciparum malaria” in this issue of Clinical Infectious Diseases, 9 of 845 Southeast Asian adults with severe malaria (1%) had bacteremia upon admission, but 4 of those 9 patients (44%) died compared with 108 of 836 (13%) nonbacteremic patients.

NOT Open Access | Evaluation of the combination of azithromycin and naphthoquine in animal malaria models

August 26, 2020 - 14:41 -- NOT Open Access
Author(s): 
Bei ZC, Li GF, Zhao JH, Zhang M, Ji XG, Wang JY
Reference: 
Antimicrob Agents Chemother. 2020 Aug 24

Combination therapy using drugs with different mechanisms of action is the current state of the art in antimalarial treatment. However, except for artemisinin-based combination therapies, only few other combinations are available now. The increasing concern on the emergence and spread of artemisinin resistance in Plasmodium falciparum has evoked a need for the development of new antimalarials.

Evaluating interventions to improve test, treat, and track (T3) malaria strategy among over-the-counter medicine sellers (OTCMS) in some rural communities of Fanteakwa North district, Ghana: study protocol for a cluster randomized controlled trial

July 13, 2020 - 16:12 -- Open Access
Author(s): 
Soniran OT, Abuaku B, Ahorlu CS
Reference: 
Trials. 2020 Jul 8;21(1):623

The World Health Organization initiated test, treat, and track (T3) malaria strategy to support malaria-endemic countries in their efforts to achieve universal coverage with diagnostic testing, antimalarial treatment, and strengthening surveillance systems. Unfortunately, T3 is not adopted by over-the-counter medicine sellers (OTCMS) where many patients with malaria-like symptoms first seek treatment. Sub-Saharan African countries are considering introducing and scaling up RDTs in these outlets to reduce malaria burden. In this context, this study is aimed at improving implementation of the T3 among OTCMS using a number of intervention tools that could be scaled-up easily at the national level.

Subscribe to RSS - antimalarial treatment